Artiva Biotherapeutics, Inc.’s Lock-Up Period To Expire on January 15th (NASDAQ:ARTV)

Artiva Biotherapeutics’ (NASDAQ:ARTV) lock-up period will end on Wednesday, January 15th. Artiva Biotherapeutics had issued 13,920,000 shares in its public offering on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. After the expiration of Artiva Biotherapeutics’ lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ARTV shares. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th. HC Wainwright assumed coverage on Artiva Biotherapeutics in a research note on Monday, December 30th. They issued a “buy” rating and a $20.00 price objective for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $21.00.

Artiva Biotherapeutics Stock Performance

NASDAQ:ARTV opened at $10.58 on Wednesday. Artiva Biotherapeutics has a 52 week low of $9.68 and a 52 week high of $17.31. The company has a fifty day moving average price of $11.37.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). Equities research analysts forecast that Artiva Biotherapeutics will post -4.68 earnings per share for the current year.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. acquired a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $623,000. BNP Paribas Financial Markets acquired a new stake in Artiva Biotherapeutics in the third quarter worth $42,000. MetLife Investment Management LLC bought a new stake in Artiva Biotherapeutics in the third quarter valued at $135,000. Acuta Capital Partners LLC acquired a new position in shares of Artiva Biotherapeutics during the third quarter valued at about $680,000. Finally, RTW Investments LP bought a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth about $2,300,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.